<DOC>
	<DOCNO>NCT00140179</DOCNO>
	<brief_summary>Valproic acid lead mood stabilizer treatment bipolar disorder . Its well-known teratogenicity limit use young woman childbearing age . According toxicologic study teratogenicity valproate stem free carboxylic group . Valnoctamide isomer analog valpromide . Unlike valpromide , valnoctamide undergo biotransformation correspond free acid . It also likely least possible valnoctamide anti-bipolar . In mice valnoctamide show distinctly less teratogenic valproate . An injection day 8 gestation produce 1 % exencephaly ( compare 0-1 % control mice 53 % valproate treat mouse ) . The investigator perform double-blind control trial valnoctamide anti-bipolar drug . If show anti-bipolar , valnoctamide could important valproate substitute young woman bipolar disorder risk pregnancy . Patients newly admit Beersheva Mental Health Center may participate meet Diagnostic Statistical Manual Mental Disorders - 4th edition ( DSM-IV ) criterion mania schizoaffective disorder , manic type . Patients admit study treat risperidone dos physician ' discretion begin 2 mg daily day 1 2 . Valnoctamide placebo begin dose 600 mg per day ( 200 mg three time daily ) increase 1200 mg ( 400 mg three time daily ) four day . Weekly rating psychiatrist blind study drug conduct use Brief Psychiatric Rating Scale ( BPRS ) , Young Mania Rating Scale ( YMS ) , Clinical Global Impression ( CGI ) . Weekly blood draw drug level valnoctamide measure gas chromatography . Each patient receive valnoctamide placebo 5 week . Low teratogenic mood stabilizer high priority current research .</brief_summary>
	<brief_title>Valnoctamide Mania</brief_title>
	<detailed_description>Valproic acid lead mood stabilizer treatment bipolar disorder . Its well-known teratogenicity limit use young woman childbearing age ( 1-3 ) . The alternative mood stabilizer lithium carbamazepine also teratogenic potential treatment bipolar disorder young woman problematic . The difficulty particularly acute young woman patient respond well anti-bipolar therapy maintain begin normal interpersonal marital relation desire child . One approach problem search valproic acid derivative less teratogenic potential ( 4 ) . According toxicologic study teratogenicity valproate stem free carboxylic group ( 2 , 3 ) . Valpromide amide derivative valproate without suspect free carboxylic group . It synthesize market anticonvulsant efficacy , least good valproic acid ( 1 ) . There report efficacy bipolar disorder well ( 5 ) . In animal specie , small amount valpromide metabolize valproic acid . However , human valpromide metabolize large degree valproic acid solve problem teratogenicity ( 1 , 6 ) . Valnoctamide isomer analog valpromide . Unlike valpromide , valnoctamide undergo biotransformation correspond free acid ( 6-9 ) . In animal study least anticonvulsant valproate valpromide ( 1 , 6 , 10 ) . It market anxiolytic sedative several European country ( Nirvanil ) include Italy , Holland Switzerland actively promote anticonvulsant . It market USA Axiquel McNeil 1970 's . Unfortunately , despite considerable effort able obtain pharmacovigilance data period . Given equivalence valproate valpromide anticonvulsant animal model epilepsy ( 1 , 6 , 10 ) , reasonable assume valnoctamide also anticonvulsant human . It also likely least possible valnoctamide anti-bipolar . In mice valnoctamide show distinctly less teratogenic valproate ( 11 ) . Injection day 8 gestation produce 1percent exencephaly ( compare 0-1percent control mice 53 percent valproate treat mouse ) . Embryolethality rate show similar result : 52 percent valproate vs. 5percent control 2 percent valnoctamide . Valnoctamide 's patent expire ( 12 ) property major pharmaceutical company . Pharmaceutical company support obtain trial ; therefore investigator initiate . Valnoctamide synthesize study Banyan Chemical India ( inspected FDA ) GLP ( good laboratory practice ) manner acceptable human use Israel Ministry Health ( principle IND FDA ) . Banyan manufacture site generic compound , atenolol instance , sell USA distribute international company , Novartis instance . Study Design : The study submit Helsinki Committee patient give inform write consent accept . Patients newly admit Beersheva Mental Health Center may participate meet DSM-IV criterion mania schizoaffective disorder , manic type . Minimal Young Mania Scale = 20 . Only patient admit hospital within previous 72 hour eligible study . Exclusion criterion previous study mania design group ( 15-17 ) include drug abuse , active physical illness , course pregnancy . Patients admit study treat risperidone dos physician ' discretion begin 2 mg daily day 1 2 . On day 3 4 risperidone dose could increase maximum 4 mg daily decrease 1mg daily . On day 5 study end dose could increase maximum 6 mg daily decrease minimum 1mg ( see ref # 18 ) . Dose risperidone secondary outcome measure ( see reference # 15 &amp; # 16 ) . No washout previous medication require patient receive depot neuroleptic within past 2 week 300 mg chlorpromazine equivalent past three day exclude . Trihexyphenidyl ( 4 mg daily ) available necessary extrapyramidal symptom benzodiazepine sleep . Valnoctamide placebo begin dose 600 mg per day ( 200 mg three time daily ) increase 1200 mg ( 400 mg three time daily ) four day . This dose base relative anticonvulsant effect valproate valnoctamide animal study ( 1 , 6 , 10 ) . Patients receive valnoctamide identical capsule placebo assign control psychiatrist accord random order ; manic schizoaffective manic patient randomize separately . Weekly rating psychiatrist blind study drug conduct use Brief Psychiatric Rating Scale ( BPRS ) , Young Mania Rating Scale ( YMS ) , Clinical Global Impression ( CGI ) . Primary outcome measure BPRS . Weekly blood draw drug level valnoctamide measure gas chromatography ( 19 ) . Each patient receive valnoctamide placebo 5 week . Power Analysis : We demonstrate significant effect add-on mania design lithium ( 15 ) , carbamazepine ( 16 ) , phenytoin ( 17 ) . Each study N 40 patient , recruit 18 month study . In study present proposal , mood stabilizer potential mood stabilizer add haloperidol dose physician 's discretion five week . Lithium add clinically statistically significant benefit haloperidol treatment mania ( 15 ) carbamazepine ( 16 ) phenytoin ( 17 ) . Such `` add-on '' design consistent clinical practice make sense since dopamine blocker mood stabilizer probably work different mechanism mania . Valproate typically use clinically acute mania add-on neuroleptic well . Three positive study publish excellent journal ( 15-17 ) group use design probably well formal power analysis , depend range assumption collapsible experience three study . Because prior probability effect valnoctamide low well-known compound , suggest recruitment 80 patient 36 month adequately power study rather 40 patient previous study . Since valnoctamide longer patented , orphan drug procedure use patent type grant Abbott divalproex sodium necessary make drug available bipolar patient risk pregnancy future . An adequately power study therefore important stage . References 1 . Bialer M , Haj-Yehia A , Badir K , Hadad S : Can develop improved derivative valproic acid ? Pharm World Sci 1994 ; 16 ( 1 ) :2-6 . 2 . Nau H , Headrick X : Valproic acid teratogenesis . ISI Atlas Sci Pharmacol 1987 ; 1:52-56 3 . Nau H , Hauck RS , Ehlers K : Valproic acid-induced neural tube defect mouse human : aspect chirality , alternative drug development , pharmacokinetics possible mechanism . Pharmacol Toxicol 1991 ; 69 ( 5 ) :310-21 . 4 . Bialer M : Pharmacokinetic consideration design good safer new antiepileptic drug . J Control Release 1999 ; 62 ( 1-2 ) :187-92 . 5 . Lemoine P , Fondarai J , Faivre T : Valpromide increase amplitude heart rate circadian rhythm remit bipolar unipolar disorder . A placebo-controlled study . Eur Psychiatry 2000 ; 15 ( 7 ) :424-32 . 6 . Bialer M : Clinical pharmacology valpromide . Clin Pharmacokinet 1991 ; 20 ( 2 ) :114-22 . 7 . Bialer M , Haj-Yehia A , Barzaghi N , Pisani F , Perucca E : Pharmacokinetics valpromide isomer , valnoctamide , healthy subject . Eur J Clin Pharmacol 1990 ; 38 ( 3 ) :289-91 . 8 . Haj-Yehia A , Bialer M : Pharmacokinetics valpromide isomer valnoctamide dog . J Pharm Sci 1988 ; 77:831-834 . 9 . Pisani F , Haj-Yehia A , Fazio A , Artesi C , Oteri G , Perucca E , Kroetz DL , Levy RH , Bialer M : Carbamazepine-valnoctamide interaction epileptic patient : vitro/in vivo correlation . Epilepsia 1993 ; 34 ( 5 ) :954-9 . 10 . Loscher W , Nau H : Pharmacological evaluation various metabolite analogue valproic acid . Anticonvulsant toxic potency mouse . Neuropharmacology 1985 ; 24 ( 5 ) :427-35 . 11 . Radatz M , Ehlers K , Yagen B , Bialer M , Nau H : Valnoctamide , valpromide valnoctic acid much less teratogenic mouse valproic acid . Epilepsy Res 1998 ; 30 ( 1 ) :41-8 . 12 . US Patent 3,056,726 ( 1962 ) : alpha-ethyl-beta-methylvaleramide mental hyperirritability . McNeil Laboratories Inc. 13 . Phiel CJ , Zhang F , Huang EY , Guenther MG , Lazar MA , Klein PS : Histone deacetylase direct target valproic acid , potent anticonvulsant , mood stabilizer , teratogen . J Biol Chem 2001 ; 276 ( 39 ) :36734-41 . 14 . Shaltiel G , Shamir A , Belmaker RH , Greenberg ML , Agam G : Valproate inhibit inositol-P synthase : mood stabilization inositol depletion elaborate . submit 15 . Biederman J , Lerner Y , Belmaker RH : Combination lithium carbonate haloperidol schizo-affective disorder : control study . Arch Gen Psychiatry 1979 ; 36 ( 3 ) :327-33 . 16 . Klein E , Bental E , Lerer B , Belmaker RH : Carbamazepine haloperidol v placebo haloperidol excite psychosis . A controlled study . Arch Gen Psychiatry 1984 ; 41 ( 2 ) :165-70 . 17 . Mishory A , Yaroslavsky Y , Bersudsky Y , Belmaker RH : Phenytoin antimanic anticonvulsant : control study . Am J Psychiatry 2000 ; 157 ( 3 ) :463-5 . 18 . Yatham LN , Grossman F , Augustyns I , Vieta E , Ravindran A : Mood stabiliser plus risperidone placebo treatment acute mania . International , double-blind , randomise control trial . Br J Psychiatry 2003 ; 182:141-7 . 19 . Bialer M , Hoch B : Rapid gas chromatographic assay monitor valnoctamide plasma . J Chromatogr 1985 ; 337:408-411 .</detailed_description>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<criteria>Ages 1860 Males female DSMIV criterion mania schizoaffective disorder , manic type Minimal Young Mania Scale = 20 Admittance hospital within previous 72 hour Any active physical illness Pregnancy Drug alcohol abuse Suicidal violent ideation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>valnoctamide</keyword>
	<keyword>teratogenicity</keyword>
	<keyword>double-blind</keyword>
	<keyword>mania</keyword>
</DOC>